Compare SRTS & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTS | ONMD |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | 60 | 23 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 56.0M |
| IPO Year | 2016 | N/A |
| Metric | SRTS | ONMD |
|---|---|---|
| Price | $3.19 | $0.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 72.2K | ★ 857.0K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,482,000.00 | N/A |
| Revenue This Year | $2.00 | N/A |
| Revenue Next Year | $34.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.82 | $0.31 |
| 52 Week High | $5.92 | $4.22 |
| Indicator | SRTS | ONMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 49.91 |
| Support Level | $3.03 | $0.92 |
| Resistance Level | $3.53 | $0.97 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 23.97 | 48.84 |
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.